Acute Myeloid Leukemia Aml Market

DelveInsight’s ‘Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Acute Myeloid Leukemia (AML), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Acute Myeloid Leukemia (AML) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Acute Myeloid Leukemia (AML) symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Acute Myeloid Leukemia (AML) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Acute Myeloid Leukemia (AML) Disease Understanding and Treatment Algorithm

Acute Myeloid Leukemia (AML) Overview

Acute myeloid leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.


AML is the most common acute leukemia in adults and primarily affects older people with a median age of diagnosis ~67 years. Each patient generally has a unique profile of cytogenetic abnormalities. Older age is associated with a higher frequency of abnormalities.


Acute Myeloid Leukemia (AML) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Acute Myeloid Leukemia (AML) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Acute Myeloid Leukemia (AML) market report thoroughly understands Acute Myeloid Leukemia (AML) symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Acute Myeloid Leukemia (AML) treatment algorithms and treatment guidelines for Acute Myeloid Leukemia (AML) symptoms in the US, Europe, and Japan.


The goal of treatment is remission, and current conventional therapeutic options for AML rely on intensive chemotherapy-based induction and consolidation therapy, together with hematopoietic stem cell transplantation. However, not all patients are eligible for intensive therapy, which can be both physically and mentally demanding, and this approach is more frequently used in healthy, younger patients. 


Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a major concern. The overall survival in the elderly population remains quite low. The multitude of chromosomal and genetic abnormalities makes the treatment of AML a challenging prospect as the heterogeneous nature of disease renders targeted agents vulnerable. The intensive chemotherapy treatments used for AML have serious side effects that many older patients cannot tolerate. These concerns warrant the development of novel therapeutics

Acute Myeloid Leukemia (AML) Epidemiology

The Acute Myeloid Leukemia (AML) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The total incident cases of Acute Myeloid Leukemia (AML) is increasing in 7MM during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted Acute Myeloid Leukemia (AML) symptoms epidemiology segmented as the Incidence of AML, Gender-specific cases of AML, Age-specific Cases of AML, and Genetic Mutations in AML. The report includes the incident scenario of Acute Myeloid Leukemia (AML) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Acute Myeloid Leukemia (AML) Epidemiology

The epidemiology segment also provides the Acute Myeloid Leukemia (AML) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total number of incident cases of Acute Myeloid Leukemia (AML) associated in 7MM countries was 41,715 in 2020.

Acute Myeloid Leukemia (AML) Drug Chapters

The Acute Myeloid Leukemia (AML) report’s drug chapter segment encloses the detailed analysis of Acute Myeloid Leukemia (AML) early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Acute Myeloid Leukemia (AML) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Acute Myeloid Leukemia (AML) Emerging Drug


Devimistat (CPI-613): Rafael Pharmaceuticals Inc.

Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613 (devimistat), targets enzymes involved in cancer cell energy metabolism and is located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent and combined with standard drug therapies in patients diagnosed with advanced solid tumors or blood cancers. Enrolment is currently underway in a Phase III clinical trial in r/r AML.


Crenolanib: Arog Pharmaceuticals

Crenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including AML, gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzimidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR α (Platelet-Derived Growth Factor Receptor), and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the ‘DFG in’ conformation motif.

Products detail in the report…

Acute Myeloid Leukemia (AML) Market Outlook

The report’s Acute Myeloid Leukemia (AML) market outlook helps build a detailed comprehension of the historic, current, and forecasted Acute Myeloid Leukemia (AML) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Acute Myeloid Leukemia (AML) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.


According to DelveInsight, the Acute Myeloid Leukemia (AML) market in 7MM is expected to grow in the study period 2018–2030.

The mainstay for the treatment of acute myeloid leukemia did not change for a long time. Cytarabine (AraC) has been the cornerstone of induction therapy and consolidation therapy for AML. A standard form of induction therapy consisted of AraC (100–200 mg/m (2)), administered by a continuous infusion for 7 days, combined with an anthracycline, administered intravenously for 3 days. This is called the “7+3” therapy. Consolidation therapy comprises treatment with additional courses of intensive chemotherapy after the patient has achieved a complete remission (CR), usually with higher doses of the same drugs as were used during the induction period. Despite substantial progress in the treatment, a high percentage of patients did not achieve remission with the standard induction chemotherapy, and many patients relapsed quickly. 


Key Findings

This section includes a glimpse of the Acute Myeloid Leukemia (AML) market in 7MM.


Acute Myeloid Leukemia (AML) market size in the seven major markets was USD 1,251.1 million in 2020.


The United States Market Outlook

This section provides the total Acute Myeloid Leukemia (AML) market size and market size by therapies in the United States.


The United States accounts for the largest market size of Acute Myeloid Leukemia (AML) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Acute Myeloid Leukemia (AML) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Acute Myeloid Leukemia (AML) market Size and market Size by therapies in Japan are also mentioned.

Acute Myeloid Leukemia (AML) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Acute Myeloid Leukemia (AML) market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Acute Myeloid Leukemia (AML) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Acute Myeloid Leukemia (AML) key players involved in developing targeted therapeutics.


Major players include Astex Pharmaceuticals, Arog Pharmaceuticals, Chimerix, Takeda, Daiichi Sankya, and others.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute Myeloid Leukemia (AML) emerging therapies.

Reimbursement Scenario in Acute Myeloid Leukemia (AML)

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.


The disease advocacy groups working in the area of AML helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.


XOSPATA (gilteritinib) is an orally bioavailable, small-molecule inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11), and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. It is approved in the US, EU, and Japan to treat adult patients who have r/r AML with an FLT3 mutation. Astellas is providing a full range of patient support services for XOSPATA in the US. XOSPATA Support Solutions offers access and reimbursement support to help patients access XOSPATA as their healthcare providers prescribe. The XOSPATA Copay Card Program is eligible for patients who have commercial prescription insurance. The program covers up to a maximum of USD 25,000 per calendar year (Astellas Pharma, n.d.). Uninsured patients may get XOSPATA at no cost under the Astellas Patient Assistance Program. In the US, it is covered under Medicare Part D and Medicare Advantage plans.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Acute Myeloid Leukemia (AML) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Acute Myeloid Leukemia (AML) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Acute Myeloid Leukemia (AML) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute Myeloid Leukemia (AML), explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Acute Myeloid Leukemia (AML) epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Myeloid Leukemia (AML) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Acute Myeloid Leukemia (AML) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Acute Myeloid Leukemia (AML) market.

Report Highlights

  • In the coming years, the Acute Myeloid Leukemia (AML) market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Acute Myeloid Leukemia (AML). The launch of emerging therapies will significantly impact the Acute Myeloid Leukemia (AML) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute Myeloid Leukemia (AML) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Myeloid Leukemia (AML) Pipeline Analysis
  • Acute Myeloid Leukemia (AML) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Myeloid Leukemia (AML) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Acute Myeloid Leukemia (AML) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Myeloid Leukemia (AML) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute Myeloid Leukemia (AML) Market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Acute Myeloid Leukemia (AML) total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Acute Myeloid Leukemia (AML) market Size during the forecast period (2018–2030)?
  • At what CAGR, the Acute Myeloid Leukemia (AML) market is expected to grow in 7MM during the forecast period (2018–2030)?
  • What would be the Acute Myeloid Leukemia (AML) market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Acute Myeloid Leukemia (AML) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Acute Myeloid Leukemia (AML)?
  • What is the historical Acute Myeloid Leukemia (AML) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute Myeloid Leukemia (AML) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Acute Myeloid Leukemia (AML)?
  • Out of all 7MM countries, which country would have the largest incident population of Acute Myeloid Leukemia (AML) during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Acute Myeloid Leukemia (AML) along with the approved therapy?
  • What are the current treatment guidelines for treating Acute Myeloid Leukemia (AML) in the USA, Europe, and Japan?
  • What are the Acute Myeloid Leukemia (AML) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Myeloid Leukemia (AML)?
  • How many therapies are developed by each company for the treatment of Acute Myeloid Leukemia (AML)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Acute Myeloid Leukemia (AML)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to Acute Myeloid Leukemia (AML) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Myeloid Leukemia (AML) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Myeloid Leukemia (AML)?
  • What are the global historical and forecasted market of Acute Myeloid Leukemia (AML)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia (AML) market.
  • To understand the future market competition in the Acute Myeloid Leukemia (AML) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia (AML) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Acute Myeloid Leukemia (AML) market.
  • To understand the future market competition in the Acute Myeloid Leukemia (AML) market.

1. Key Insights

2. Report Introduction

3. Acute Myeloid Leukemia (AML) Market Overview at a Glance

3.1. Market Share (%) Distribution of Acute Myeloid Leukemia in 2018

3.2. Market Share (%) Distribution of Acute Myeloid Leukemia in 2030

4. Executive Summary of Acute Myeloid Leukemia (AML)

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Symptoms

5.4. Causes

5.5. Risk Factors

5.6. Pathophysiology

5.7. Gene mutations Associated With AML

5.8. Diagnosis

5.8.1. Diagnostic Algorithm

5.8.2. Diagnostic Guidelines

5.9. Prognosis Factors

5.10. Treatment

5.10.1. Treatment Guideline

5.10.1.1. AML in Adult Patients: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.10.1.2. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Population of Acute Myeloid Leukemia

6.3. Epidemiology of Acute Myeloid Leukemia

6.4. The United States

6.4.1. Incidence of AML in the United States

6.4.2. Gender-specific cases in the United States

6.4.3. Age-specific cases in the United States

6.4.4. Genetic Mutations in AML in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Incidence of AML in Germany

6.5.1.2. Gender-specific cases in Germany

6.5.1.3. Age-specific cases in Germany

6.5.1.4. Genetic Mutations in AML in Germany

6.5.2. France

6.5.2.1. Incidence of AML in France

6.5.2.2. Gender-specific cases in France

6.5.2.3. Age-specific cases in France

6.5.2.4. Genetic Mutations in AML in France

6.5.3. Italy

6.5.3.1. Incidence of AML in Italy

6.5.3.2. Gender-specific cases in Italy

6.5.3.3. Age-specific cases in Italy

6.5.3.4. Genetic Mutations in AML in Italy

6.5.4. Spain

6.5.4.1. Incidence of AML in Spain

6.5.4.2. Gender-specific cases in Spain

6.5.4.3. Age-specific cases in Spain

6.5.4.4. Genetic Mutations in AML in Spain

6.5.5. United Kingdom

6.5.5.1. Incidence of AML in the United Kingdom

6.5.5.2. Gender-specific cases in the United Kingdom

6.5.5.3. Age-specific cases in the United Kingdom

6.5.5.4. Genetic Mutations in AML in the United Kingdom

6.6. Japan

6.6.1. Incidence of AML in Japan

6.6.2. Gender-specific cases of AML in Japan

6.6.3. Age-specific cases of AML in Japan

6.6.4. Genetic Mutations in AML in Japan

7. Organizations contributing towards Acute Myeloid Leukemia (AML)

8. Case Reports

9. Patient Journey

10. Marketed Therapies

10.1. Daurismo (Glasdegib): Pfizer

10.1.1. Product Description

10.1.2. Mechanism of action

10.1.3. Regulatory Milestones

10.1.4. Safety and Efficacy of Daurismo

10.1.5. Side effects of Daurismo

10.1.6. Product Profile

10.2. IDHIFA (Enasidenib): Bristol Myers Squibb

10.2.1. Product Description

10.2.2. Mechanism of action

10.2.3. Regulatory Milestones

10.2.4. Safety and Efficacy of IDHIFA

10.2.5. Side effects of IDHIFA

10.2.6. Product Profile

10.3. TIBSOVO (Ivosidenib): Agios Pharmaceuticals

10.3.1. Product Description

10.3.2. Mechanism of action

10.3.3. Regulatory Milestones

10.3.4. Safety and Efficacy of TIBSOVO

10.3.5. Side effects of TIBSOVO

10.3.6. Product Profile

10.4. VENCLEXTA (Venetoclax): Abbvie

10.4.1. Product Description

10.4.2. Mechanism of action

10.4.3. Regulatory Milestones

10.4.4. Safety and Efficacy of VENCLEXTA

10.4.5. Side effects of VENCLEXTA

10.4.6. Product Profile

10.5. VYXEOS (Daunorubicin and Cytarabine): Jazz Pharmaceuticals

10.5.1. Product Description

10.5.2. Mechanism of action

10.5.3. Regulatory Milestones

10.5.4. Safety and Efficacy of VYXEOS

10.5.5. Side Effects of VYXEOS

10.5.6. Product Profile

10.6. XOSPATA (Gilteritinib): Astellas Pharma

10.6.1. Product Description

10.6.2. Mechanism of action

10.6.3. Regulatory Milestones

10.6.4. Safety and Efficacy of XOSPATA

10.6.5. Side Effects of XOSPATA

10.6.6. Product Profile

10.7. MYLOTARG (Gemtuzumab ozogamicin): Pfizer

10.7.1. Product Description

10.7.2. Mechanism of action

10.7.3. Regulatory Milestones

10.7.4. Safety and Efficacy of MYLOTARG

10.7.5. Side effects of MYLOTARG

10.7.6. Product Profile

10.8. RYDAPT (Midostaurin): Novartis Oncology

10.8.1. Product Description

10.8.2. Mechanism of action

10.8.3. Regulatory Milestones

10.8.4. Safety and Efficacy of RYDAPT

10.8.5. Side effects of RYDAPT

10.8.6. Product Profile

10.9. VANFLYTA (Quizartinib): Daiichi Sankyo.

10.9.1. Product Description

10.9.2. Mechanism of action

10.9.3. Regulatory Milestones

10.9.4. Safety and Efficacy of VANFLYTA

10.9.5. Product Profile

10.10. ONUREG (Azacitidine): Bristol Myers Squibb

10.10.1. Product Description

10.10.2. Mechanism of action

10.10.3. Regulatory Milestones

10.10.4. Safety and Efficacy of ONUREG

10.10.5. Side effects of ONUREG

10.10.6. Product Profile

11. Emerging Therapies

11.1. Key-Cross: Emerging drugs

11.1.1. Induction and Maintenance drugs

11.1.2. Drugs for Relapsed Patients

11.1.3. Other Assets

11.2. Inqovi (ASTX727 [Decitabine and cedazuridine]): AstraZeneca/Astex Pharmaceuticals, Inc.

11.2.1. Drug Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Product Profile

11.3. Dociparstat sodium (DSTAT, CX-01): Chimerix

11.3.1. Drug Description

11.3.2. Other development activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. Pevonedistat (TAK-924, MLN4924): Takeda

11.4.1. Drug Description

11.4.2. Other Developmental Activities

11.4.3. Clinical development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. Devimistat (CPI-613): Rafael Pharmaceuticals Inc.

11.5.1. Drug Description

11.5.2. Other development activities

11.5.3. Clinical Development

11.5.4. Safety and Efficacy

11.5.5. Product Profile

11.6. Radgocitabine (DFP-10917): Delta-Fly Pharma

11.6.1. Drug Description

11.6.2. Other development activities

11.6.3. Clinical Development

11.6.4. Safety and Efficacy

11.6.5. Product Profile

11.7. Uproleselan: GlycoMimetics Incorporated

11.7.1. Drug Description

11.7.2. Other development activities

11.7.3. linical Development

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. Bemcentinib: BerGenBio ASA

11.8.1. Drug Description

11.8.2. Other development activities

11.8.3. Clinical Development

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. Flotetuzumab (MGD006): MacroGenics

11.9.1. Product Description

11.9.2. Other Developmental Activities

11.9.3. Clinical Development

11.9.4. Safety and Efficacy

11.9.5. Product Profile

11.10. SNDX-5613: Syndax Pharmaceuticals

11.10.1. Product Description

11.10.2. Other Developmental Activities

11.10.3. Clinical Development

11.10.4. Safety and Efficacy

11.10.5. Product Profile

11.11. Crenolanib: Arog Pharmaceuticals

11.11.1. Drug Description

11.11.2. Regulatory Milestones

11.11.3. Clinical Development

11.11.4. Safety and Efficacy

11.11.5. Product Profile

11.12. Olutasidenib (FT-2102): Forma Therapeutics

11.12.1. Product Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.4. Safety and Efficacy

11.12.5. Product Profile

11.13. Galinpepimut-S: Sellas Life Sciences Group

11.13.1. Drug Description

11.13.2. Regulatory Milestones

11.13.3. Clinical Development

11.13.4. Safety and Efficacy

11.13.5. Product Profile

11.14. Iomab-B: Actinium Pharmaceuticals

11.14.1. Drug Description

11.14.2. Regulatory Milestones

11.14.3. Clinical Development

11.14.4. Safety and Efficacy

11.14.5. Product Profile

12. Other Promising Therapies

12.1. Brequinar: Clear Creek Bio Inc.

12.1.1. Drug Description

12.1.2. Clinical development

12.1.3. Product Profile

12.2. CCS1477: CellCentric Ltd.

12.2.1. Drug Description

12.2.2. Clinical development

12.2.3. Safety and Efficacy

12.2.4. Product Profile

12.3. Aspacytarabine (BST-236): Biosight Ltd.

12.3.1. Drug Description

12.3.2. Other development activities

12.3.3. Clinical development

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. Azacitidine and Cedazuridine (ASTX030): Astex Pharmaceuticals, Inc.

12.4.1. Drug Description

12.4.2. Clinical Development

12.4.3. Product Profile

12.5. CA-4948: Curis, Inc.

12.5.1. Drug Description

12.5.2. Other development activities

12.5.3. Clinical Development

12.5.4. Safety and Efficacy

12.5.5. Product Profile

12.6. NEXI-001: NexImmune Inc.

12.6.1. Drug Description

12.6.2. Other development activities

12.6.3. Clinical Development

12.6.4. Product Profile

12.7. OPB-111077: Immunomedics, Inc.

12.7.1. Drug Description

12.7.2. Clinical Development

12.7.3. Safety and Efficacy

12.7.4. Product Profile

12.8. Alvocidib: Sumitomo Dainippon Pharma Co., Ltd.

12.8.1. Drug Description

12.8.2. Other development activities

12.8.3. Clinical Development

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. Ruxolitinib: Incyte Corporation

12.9.1. Product Description

12.9.2. Clinical Development

12.9.3. Product Profile

12.10. Eprenetapopt (APR-246): Aprea Therapeutics

12.10.1. Drug Description

12.10.2. Other development activities

12.10.3. Clinical Development

12.10.4. Safety and Efficacy

12.10.5. Product Profile

12.11. DCP-001: Immunicum/DCPrime BV

12.11.1. Product Description

12.11.2. Other Developmental Activities

12.11.3. Clinical Development

12.11.4. Safety and Efficacy

12.11.5. Product Profile

12.12. GTB-3550 (OXS-3550): GT Biopharma, Inc.

12.12.1. Product Description

12.12.2. Other Developmental Activities

12.12.3. Clinical Development

12.12.4. Safety and Efficacy

12.12.5. Product Profile

12.13. HM43239: Hanmi Pharmaceutical Company Limited

12.13.1. Product Description

12.13.2. Other Developmental Activities

12.13.3. Clinical Development

12.13.4. Product Profile

12.14. Onvansertib (PCM-075): Cardiff Oncology

12.14.1. Product Description

12.14.2. Other Developmental Activities

12.14.3. Clinical Development

12.14.4. Safety and Efficacy

12.14.5. Product Profile

12.15. Prexigebersen (Liposomal Grb2 Antisense, BP1001): Bio-Path Holdings

12.15.1. Product Description

12.15.2. Other Developmental Activities

12.15.3. Clinical Development

12.15.4. Safety and Efficacy

12.15.5. Product Profile

12.16. Lintuzumab-Ac225 (Actimab-A/Ac-225): Actinium Pharmaceuticals

12.16.1. Product Description

12.16.2. Other Developmental Activities

12.16.3. Clinical Development

12.16.4. Safety and Efficacy

12.16.5. Product Profile

12.17. APVO436: Aptevo Therapeutics

12.17.1. Drug Description

12.17.2. Other development activities

12.17.3. Clinical development

12.17.4. Safety and Efficacy

12.17.5. Product Profile

12.18. FLYSYN: Synimmune GmbH

12.18.1. Drug Description

12.18.2. Other development activities

12.18.3. Clinical Development

12.18.4. Safety and Efficacy

12.18.5. Product Profile

12.19. GEM333: GEMoaB Monoclonals

12.19.1. Drug Description

12.19.2. Other development activities

12.19.3. Clinical Development

12.19.4. Product Profile

12.20. IMGN632: ImmunoGen, Inc.

12.20.1. Drug Description

12.20.2. Other development activities

12.20.3. Clinical Development

12.20.4. Safety and Efficacy

12.20.5. Product Profile

12.21. MLM-CAR44.1 T-Cells (CD44v6): AGC Biologics S.p.A.

12.21.1. Drug Description

12.21.2. Other development activities

12.21.3. Clinical Development

12.21.4. Product Profile

12.22. PRGN-3006: Precigen, Inc.

12.22.1. Drug Description

12.22.2. Other development activities

12.22.3. Clinical Development

12.22.4. Safety and Efficacy

12.22.5. Product Profile

12.23. Sabatolimab (MBG453): Novartis Pharmaceuticals

12.23.1. Drug Description

12.23.2. Other development activities

12.23.3. Clinical Development

12.23.4. Safety and Efficacy

12.23.5. Product Profile

12.24. Vibecotamab (XmAb14045): Xencor, Inc./Novartis

12.24.1. Drug Description

12.24.2. Other development activities

12.24.3. Clinical Development

12.24.4. Safety and Efficacy

12.24.5. Product Profile

12.25. GSPT1 CELMoD (CC-90009): Celgene/Bristol Myers Squibb

12.25.1. Drug Description

12.25.2. Other development activities

12.25.3. Clinical Development

12.25.4. Safety and Efficacy

12.25.5. Product Profile

13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Acute Myeloid Leukemia (AML) in 7MM

13.3. Market Outlook

13.4. United States Market Size

13.4.1. Total Market Size of Acute Myeloid Leukemia (AML) in the United States

13.4.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in the United States

13.4.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in the United States

13.4.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in the United States

13.5. EU-5 Market Size

13.5.1. Germany

13.5.1.1. Total Market Size of Acute Myeloid Leukemia (AML) in Germany

13.5.1.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in Germany

13.5.1.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in Germany

13.5.1.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in Germany

13.5.2. France

13.5.2.1. Total Market Size of Acute Myeloid Leukemia (AML) in France

13.5.2.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in France

13.5.2.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in France

13.5.2.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in France

13.5.3. Italy

13.5.3.1. Total Market Size of Acute Myeloid Leukemia (AML) in Italy

13.5.3.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in Italy

13.5.3.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in Italy

13.5.3.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in Italy

13.5.4. Spain

13.5.4.1. Total Market Size of Acute Myeloid Leukemia (AML) in Spain

13.5.4.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in Spain

13.5.4.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in Spain

13.5.4.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in Spain

13.5.5. United Kingdom

13.5.5.1. Total Market Size of Acute Myeloid Leukemia (AML) in the United Kingdom

13.5.5.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in the United Kingdom

13.5.5.3. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in the United Kingdom

13.5.5.4. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in the United Kingdom

13.6. Japan

13.6.1. Total Market size of Acute Myeloid Leukemia (AML) in Japan

13.6.2. Market Size of Acute Myeloid Leukemia (AML) by Therapies in Japan

13.6.1. Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in Japan

13.6.2. Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Market Access

19. KOL Views

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Acute Myeloid Leukemia, Market, Epidemiology, and Key Events (2018–2030)

Table 2: FAB Classification of AML

Table 3: WHO Classification of AML and Related Neoplasms

Table 4: Frequency and Clinical Significance of Recurrent Gene Mutations in Adults With AML

Table 5: Tests/procedures for a patient with AML

Table 6: Updated AML Risk Classification From the NCCN and ELN

Table 7: Total Incident Population of Acute Myeloid Leukemia in 7MM (2018–2030)

Table 8: Incidence of AML in the United States (2018–2030)

Table 9: Gender-specific cases of AML in the United States (2018–2030)

Table 10: Age-specific Cases of AML in the United States (2018–2030)

Table 11: Genetic Mutations in AML in the United States (2018–2030)

Table 12: Incidence of AML in Germany (2018–2030)

Table 13: Gender-specific cases of AML in Germany (2018–2030)

Table 14: Age-specific cases of AML in Germany (2018–2030)

Table 15: Genetic Mutations in AML in Germany (2018–2030)

Table 16: Incidence of AML in France (2018–2030)

Table 17: Gender-specific cases of AML in France (2018–2030)

Table 18: Age-specific cases of AML in France (2018–2030)

Table 19: Genetic Mutations in AML in France (2018–2030)

Table 20: Incidence of AML in Italy (2018–2030)

Table 21: Gender-specific cases of AML in Italy (2018–2030)

Table 22: Age-specific cases of AML in Italy (2018–2030)

Table 23: Genetic Mutations in AML in Italy (2018–2030)

Table 24: Incidence of AML in Spain (2018–2030)

Table 25: Gender-specific cases of AML in Spain (2018–2030)

Table 26: Age-specific cases of AML in Spain (2018–2030)

Table 27: Genetic Mutations in AML in Spain (2018–2030)

Table 28: Incidence of AML in the United Kingdom (2018–2030)

Table 29: Gender-specific cases of AML in the United Kingdom (2018–2030)

Table 30: Age-specific cases of AML in the United Kingdom (2018–2030)

Table 31: Genetic Mutations in AML in the United Kingdom (2018–2030)

Table 32: Incidence of AML in Japan (2018–2030)

Table 33: Gender-specific cases of AML in Japan (2018–2030)

Table 34: Age-specific cases of AML in Japan (2018–2030)

Table 35: Genetic Mutations in AML in Japan (2018–2030)

Table 36: Organizations contributing toward the fight against Acute Myeloid Leukemia

Table 37: ASTX727, Clinical Trial Description, 2021

Table 38: Dociparstat sodium (DSTAT, CX-01), Clinical Trial Description, 2021

Table 39: Pevonedistat (TAK-924), Clinical Trial Description, 2021

Table 40: Devimistat, Clinical Trial Description, 2021

Table 41: DFP-10917, Clinical Trial Description, 2021

Table 42: Uproleselan, Clinical Trial Description, 2021

Table 43: Bemcentinib, Clinical Trial Description, 2021

Table 44: Flotetuzumab, Clinical Trial Description, 2021

Table 45: SNDX-5613, Clinical Trial Description, 2021

Table 46: Crenolanib, Clinical Trial Description, 2021

Table 47: FT-2102, Clinical Trial Description, 2021

Table 48: Galinpepimut-S, Clinical Trial Description, 2021

Table 49: Iomab-B, Clinical Trial Description, 2021

Table 50: Brequinar, Clinical Trial Description, 2021

Table 51: CCS1477, Clinical Trial Description, 2021

Table 52: Aspacytarabine, Clinical Trial Description, 2021

Table 53: ASTX030, Clinical Trial Description, 2021

Table 54: CA-4948, Clinical Trial Description, 2021

Table 55: NEXI-001, Clinical Trial Description, 2021

Table 56: OPB-111077, Clinical Trial Description, 2021

Table 57: Alvocidib, Clinical Trial Description, 2021

Table 58: Durvalumab + Other Therapy, Clinical Trial Description, 2021

Table 59: Eprenetapopt (APR-246), Clinical Trial Description, 2021

Table 60: DCP-001, Clinical Trial Description, 2021

Table 61: GTB-3550 TriKE, Clinical Trial Description, 2021

Table 62: HM43239, Clinical Trial Description, 2021

Table 63: Onvansertib, Clinical Trial Description, 2021

Table 64: Prexigebersen (Liposomal Grb2 Antisense, BP1001), Clinical Trial Description, 2021

Table 65: Lintuzumab-Ac225, Clinical Trial Description, 2021

Table 66: APVO436, Clinical Trial Description, 2021

Table 67: FLYSYN, Clinical Trial Description, 2021

Table 68: GEM333, Clinical Trial Description, 2021

Table 69: IMGN632, Clinical Trial Description, 2021

Table 70: MLM-CAR44.1 T-cells, Clinical Trial Description, 2021

Table 71: PRGN-3006 T-cells, Clinical Trial Description, 2021

Table 72: Sabatolimab, Clinical Trial Description, 2021

Table 73: XmAb14045, Clinical Trial Description, 2021

Table 74: CC-90009, Clinical Trial Description, 2021

Table 75: 7 Major Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 76: The United States Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 77: The United States Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 78: The United States Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 79: The United States Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 80: Germany Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 81: Germany Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 82: Germany Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 83: Germany Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 84: France Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 85: France Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 86: France Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 87: France Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 88: Italy Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 89: Italy Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 90: Italy Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 91: Italy Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 92: Spain Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 93: Spain Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 94: Spain Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 95: Spain Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 96: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 97: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 98: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 99: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 100: Japan Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Table 101: Japan Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Table 102: Japan Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Table 103: Japan Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Table 104: Relevant Billing and Coding Information for MYLOTARG

Table 105: Reimbursement Information of IDHIFA (Enasidenib)

List of Figures

Figure 1: Development of Blood Cells.

Figure 2: Causes of CRS

Figure 3: Eight Functional Categories of Genes that are Commonly Mutated in AML.

Figure 4: Eight Functional Categories of Genes That are Commonly Mutated in AML.

Figure 5: Diagnostic Algorithm of AML.

Figure 6: Acute Leukemia Diagnostic Journey

Figure 7: Treatment Algorithm for First-Line Treatment in Newly Diagnosed AML Patients Eligible for Standard Induction and Consolidation Treatment

Figure 8: Treatment Algorithm for First-Line Treatment in Newly Diagnosed AML Patients not Eligible for Standard Induction and Consolidation Treatment

Figure 9: Treatment Algorithm for Second-Line Treatment in Relapsed/Refractory AML Patients

Figure 10: Treatment Induction (Physiologic Age <60 Years)

Figure 11: AML Physiologic Age <60 Years After Standard Dose Cytarabine Induction/Reinduction

Figure 12: AML Physiologic Age <60 Years After High Dose Cytarabine Induction

Figure 13: Post Remission/Maintenance Therapy (Physiologic Age <60 Years)

Figure 14: Treatment Induction (Physiologic Age ≥60 Years)

Figure 15: Treatment Induction (Physiologic Age ≥60 Years)

Figure 16: Standard Dose Cytarabine Induction (Physiologic Age ≥60 Years)

Figure 17: Post remission/Maintenance Therapy (Physiologic Age ≥60 Years)

Figure 18: Post-induction Therapy (Physiologic Age ≥ 60 Years)

Figure 19: AML Surveillance and Therapy for Relapse/Refractory (After Completion of Consolidation)

Figure 20: Total Incident Population of Acute Myeloid Leukemia in 7MM (2018–2030)

Figure 21: Incidence of AML in the United States (2018–2030)

Figure 22: Gender-specific cases of AML in the United States (2018–2030)

Figure 23: Age-specific Cases of AML in the United States (2018–2030)

Figure 24: Genetic Mutations in AML in the United States (2018–2030)

Figure 25: Incidence of AML in Germany (2018–2030)

Figure 26: Gender-specific cases of AML in Germany (2018–2030)

Figure 27: Age-specific cases of AML in Germany (2018–2030)

Figure 28: Genetic Mutations in AML in Germany (2018–2030)

Figure 29: Incidence of AML in France (2018–2030)

Figure 30: Gender-specific cases of AML in France (2018–2030)

Figure 31: Age-specific cases of AML in France (2018–2030)

Figure 32: Genetic Mutations in AML in France (2018–2030)

Figure 33: Incidence of AML in Italy (2018–2030)

Figure 34: Gender-specific cases of AML in Italy (2018–2030)

Figure 35: Age-specific cases of AML in Italy (2018–2030)

Figure 36: Genetic Mutations in AML in Italy (2018–2030)

Figure 37: Incidence of AML in Spain (2018–2030)

Figure 38: Gender-specific cases of AML in Spain (2018–2030)

Figure 39: Age-specific cases of AML in Spain (2018–2030)

Figure 40: Genetic Mutations in AML in Spain (2018–2030)

Figure 41: Incidence of AML in the United Kingdom (2018–2030)

Figure 42: Gender-specific cases of AML in the United Kingdom (2018–2030)

Figure 43: Age-specific cases of AML in the United Kingdom in 000s (2018–2030)

Figure 44: Genetic Mutations in AML in the United Kingdom (2018–2030)

Figure 45: Incidence of AML in Japan (2018–2030)

Figure 46: Gender-specific cases of AML in Japan in 000s (2018–2030)

Figure 47: Age-specific cases of AML in Japan (2018–2030)

Figure 48: Genetic Mutations in AML in Japan (2018–2030)

Figure 49: 7 Major Market Size of Acute Myeloid Leukemia (AML) in USD Million (2018–2030)

Figure 50: Market Size of Acute Myeloid Leukemia (AML) in the United States,

Figure 51: The United States Market Size of Acute Myeloid Leukemia (AML) by Therapies in

Figure 52: The United States Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in

Figure 53: The United States Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

Figure 54: Market Size of Acute Myeloid Leukemia (AML) in Germany

Figure 55: Germany Market Size of Acute Myeloid Leukemia (AML) by Therapies in

Figure 56: Germany Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in

Figure 57: Germany Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

Figure 58: Market Size of Acute Myeloid Leukemia (AML) in France, USD Million (2018–2030)

Figure 59: France Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Figure 60: France Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in

Figure 61: France Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

Figure 62: Market Size of Acute Myeloid Leukemia (AML) in Italy, USD Million (2018–2030)

Figure 63: Italy Market Size of Acute Myeloid Leukemia (AML) by Therapies in

Figure 64: Italy Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in

Figure 65: Italy Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

Figure 66: Market Size of Acute Myeloid Leukemia (AML) in Spain, USD Million (2018–2030)

Figure 67: Spain Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million

Figure 68: Spain Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in

Figure 69: Spain Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

Figure 70: Market Size of Acute Myeloid Leukemia (AML) in the United Kingdom, USD Million (2018–2030)

Figure 71: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Figure 72: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Figure 73: The United Kingdom Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in USD Million (2018–2030)

Figure 74: Market Size of Acute Myeloid Leukemia (AML) in Japan, USD Million (2018–2030)

Figure 75: Japan Market Size of Acute Myeloid Leukemia (AML) by Therapies in USD Million (2018–2030)

Figure 76: Japan Market Size of Acute Myeloid Leukemia (AML) by Current Therapies in USD Million (2018–2030)

Figure 77: Japan Market Size of Acute Myeloid Leukemia (AML) by Emerging Therapies in

• Pfizer

• Bristol Myers Squibb

• Agios Pharmaceuticals

• Abbvie

• Jazz Pharmaceuticals

• Astellas Pharma

• Pfizer

• Novartis Oncology

• Daiichi Sankyo.

• Bristol Myers Squibb

• AstraZeneca/Astex Pharmaceuticals, Inc.

• Chimerix

• Takeda

• Rafael Pharmaceuticals Inc.

• Delta-Fly Pharma

• GlycoMimetics Incorporated

• BerGenBio ASA

• MacroGenics

• Syndax Pharmaceuticals

• Arog Pharmaceuticals

• Forma Therapeutics

• Sellas Life Sciences Group

• Actinium Pharmaceuticals

• Clear Creek Bio Inc.

• CellCentric Ltd.

• Biosight Ltd.

• Astex Pharmaceuticals, Inc.

• Curis, Inc.

• NexImmune Inc.

• Immunomedics, Inc.

• Sumitomo Dainippon Pharma Co., Ltd.

• Incyte Corporation

• Aprea Therapeutics

• Immunicum/DCPrime BV

• GT Biopharma, Inc.

• Hanmi Pharmaceutical Company Limited

• Cardiff Oncology

• Bio-Path Holdings

• Actinium Pharmaceuticals

• Aptevo Therapeutics

• Synimmune GmbH

• GEMoaB Monoclonals

• ImmunoGen, Inc.

• AGC Biologics S.p.A.

• Precigen, Inc.

• Novartis Pharmaceuticals

• Xencor, Inc./Novartis

• Celgene/Bristol Myers Squibb

  • Tags:
  • Acute Myeloid Leukemia (AML) market
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia (AML) marke...
  • Acute Myeloid Leukemia (AML) marke...
  • Acute Myeloid Leukemia (AML) marke...
  • Acute Myeloid Leukemia (AML) marke...
  • Acute Myeloid Leukemia (AML) pipel...
  • Acute Myeloid Leukemia (AML) treat...
  • Acute Myeloid Leukemia (AML) drugs
  • Acute Myeloid Leukemia (AML) sales...
  • Acute Myeloid Leukemia (AML) marke...
  • Acute Myeloid Leukemia (AML) disea...
  • Acute Myeloid Leukemia (AML) epide...
  • Acute Myeloid Leukemia (AML)

Forward to Friend

Need A Quote